News >

TAS-102 Improves Survival in Asian mCRC Patients

Jason Harris
Published: Friday, Jan 12, 2018

TAS-102 (trifluridine and tipiracil; Lonsurf) improved overall survival (OS) compared with placebo in previously treated Asian patients with metastatic colorectal cancer (mCRC), according to findings from the phase III TERRA trial published in the Journal of Clinical Oncology.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x